Glucagon's Broad Potential: A New Path for Obesity and Metabolic Diseases

Glucagon is traditionally known for its role in raising blood glucose, but recent research highlights its broader metabolic functions. The increasing global burden of obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and other cardio-kidney-metabolic (CKM) conditions necessitates novel therapeutic strategies. This review explores the shared mechanistic pathways of glucagon signaling that could unlock its potential for treating these complex diseases.

The review highlighted that glucagon receptor activation can lead to significant metabolic benefits beyond its glucose-raising effects. Studies discussed demonstrated that glucagon receptor agonists (GRAs) or dual GLP-1/glucagon receptor agonists consistently promote weight loss, often achieving 10-15% body weight reduction in preclinical models and early human trials involving 200-500 subjects. Furthermore, these agents were shown to reduce hepatic steatosis (liver fat accumulation) by 30-50% and improve insulin sensitivity by 20-30% in various models of MASLD over treatment periods of 8-12 weeks. The review also noted improvements in renal function markers (e.g., 20% reduction in albuminuria) and cardiovascular risk factors (e.g., 15% decrease in triglycerides), suggesting a broad protective effect. The most compelling finding is the identification of shared downstream signaling pathways, such as increased energy expenditure and enhanced lipid metabolism, that underpin glucagon's therapeutic potential across obesity, MASLD, and cardio-kidney-metabolic conditions.